Folate-Targeted Photodynamic Therapeutic Agents for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgery, radiation therapy, and chemotherapy, are often ineffective against metastatic disease and result in significant side effects due to non-specific targeting of healthy cells, leading to a need for more potent and safer methods that can selectively target cancer cells while minimizing damage to healthy tissues.
Innovation Solution
Development of folate-targeted photodynamic therapeutic agents conjugated with a linker to guide them to specific organelles within cancer cells, such as mitochondria or the nucleus, to enhance water solubility and bioavailability, and release the therapeutic agent inside the cells, thereby avoiding efflux pumps and increasing treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapies are used to treat cancer, then malignant cells can be killed, but healthy cells are also damaged causing significant side effects
Solution Approach 1:
The patent applies local quality by modifying the chemotherapy agent to have different properties at different locations: the parent compound provides cytotoxic activity, while the conjugated folate ligand provides target-specific binding to folate receptors on cancer cells. This spatial differentiation of function allows selective delivery of the toxic agent to malignant cells while sparing healthy tissues.
Solution Approach 2:
The folate ligand acts as an intermediary that mediates between the chemotherapy agent and the cancer cell. It binds specifically to folate receptors on the cancer cell surface, forming a complex that is internalized via receptor-mediated endocytosis, thereby delivering the cytotoxic agent selectively to the target cell without requiring direct contact between the drug and healthy cells.
2Ease of operation
If non-targeted photodynamic therapeutic agents are used, then treatment can be administered, but specificity to cancer cells is low resulting in off-target toxicity
Solution Approach 1:
The patent creates a composite therapeutic agent by conjugating the photodynamic therapeutic agent (Bphed-a or Visudyne) with a folate ligand through a linker. This composite structure combines the photodynamic activity of the parent compound with the target-specific binding properties of folate, enabling both easy administration and high specificity to cancer cells expressing folate receptors.
3Productivity
If cytotoxic drugs are distributed indiscriminately to all cells, then cancer cells can be reached, but healthy cells are also affected causing collateral damage
Solution Approach 1:
The patent applies preliminary action by pre-conjugating the cytotoxic agent with the folate ligand before administration. This pre-targeting strategy ensures that the drug is already equipped with navigation capabilities to find and bind to folate receptors on cancer cells, eliminating the need for indiscriminate distribution throughout the body and preventing collateral damage from the outset.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The folate-targeted photodynamic therapeutic agents demonstrate high specificity and efficacy in targeting cancer cells, reducing side effects by minimizing exposure to healthy tissues and achieving complete tumor eradication with improved pharmacokinetic properties and fluorescence imaging capabilities.
Implementation Method 1
photodynamic therapeutic (PDT) agents for the treatment of tumors
Implementation Method 2
photodynamic therapeutic agent that comprises a folate or pteroyl ligand, an amino acid, a releasable linker, an organelle-targeting agent, and a photodynamic therapeutic agent
Data Source
AI summary
The present invention describes new compounds that are useful for image-guided surgery and photodynamic therapy. In particular the compounds may be targeted to the nucleus or the mitochondria after compounds were delivered to diseased tissues such as cancer using a ligand that target receptor that express on the diseased tissue and followed by receptor mediated endocytosis and provide effective activity against cancer cells as well as other disorders. Methods and compositions for use of the same are described.